EVO
Evotec SE
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · DE
$1.42
+2.90%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.44
From 52W high−65.78%
Volume77569.00
Market cap$504.65M
P/E (TTM)—
P/S (TTM)0.6x
Div yield—
Key dataOct 19, 2026
Open
$1.44
From 52W high
−65.78%
Volume
77569.00
Market cap
$504.65M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.4x
P/E (TTM)
—
RSI (14)
36.2
MomentumView details →
1D Return
+2.90%
YTD Return
−54.22%
SummaryUpdated Jun 1, 2026
Evotec SE (NASDAQ:EVO) is a German drug discovery and development company founded in 1993 and headquartered in Hamburg. Originally incorporated as Evotec AG, the company changed its name to Evotec SE in April 2019 and went public in 2004. Evotec operates as a strategic partner to pharmaceutical and biotechnology companies worldwide, providing integrated drug discovery services and biologics manufacturing capabilities. The company has evolved from a traditional contract research organization into a technology-driven platform that combines advanced scientific capabilities with manufacturing expertise to accelerate drug development across multiple therapeutic areas.
Similar companies
Latest newsMore news →
Evotec SE announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, with a search for his successor ongoing.21d agoEvotec SE initiated a Phase 1 clinical trial for JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its subsidiary Just - Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.41d ago